Phosphodiesterase-5-inhibitors compared

被引：0
|
作者：
不详
机构：
来源：
AKTUELLE UROLOGIE | 2005年 / 36卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Novel indications for phosphodiesterase type 5 inhibitors
    Rosenkranz, Stephan
    Caglayan, Evren
    Erdmann, Erland
    MEDIZINISCHE KLINIK, 2007, 102 (08) : 617 - 630
  • [32] Phosphodiesterase 5 inhibitors in male sexual dysfunction
    Kuthe, A
    CURRENT OPINION IN UROLOGY, 2003, 13 (05) : 405 - 410
  • [33] Editorial: Tachyphylaxis and phosphodiesterase type 5 inhibitors
    Steers, WD
    JOURNAL OF UROLOGY, 2002, 168 (01): : 207 - 207
  • [34] Optimizing response to phosphodiesterase type 5 inhibitors
    Sadovsky R.
    Current Sexual Health Reports, 2007, 4 (1) : 1 - 6
  • [35] The use of phosphodiesterase 5 inhibitors with concomitant medications
    Corona, G.
    Razzoli, E.
    Forti, G.
    Maggi, M.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (09) : 799 - 808
  • [36] Phosphodiesterase 5 inhibitors in vascular systemic disorders
    Allanore, Yannick
    JOINT BONE SPINE, 2012, 79 (04) : 338 - 340
  • [37] Phosphodiesterase-5 Inhibitors: Future Perspectives
    Konstantinos, Giannitsas
    Petros, Perimenis
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (30) : 3540 - 3551
  • [38] Phosphodiesterase type 5 inhibitors and kidney disease
    Afsar, Baris
    Ortiz, Alberto
    Covic, Adrian
    Gaipov, Abduzhappar
    Esen, Tarik
    Goldsmith, David
    Kanbay, Mehmet
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2015, 47 (09) : 1521 - 1528
  • [39] Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors
    Jackson, G
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (12B): : 32M - 36M
  • [40] ADMET considerations for phosphodiesterase-5 inhibitors
    Rezvanfar, Mohammad Amin
    Rahimi, Hamid Reza
    Abdollahi, Mohammad
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (10) : 1231 - 1245
12345